Blood Reviews
Volume 20, Issue 2 , Pages 83-92 , March 2006

Oligosaccharide structures of von Willebrand factor and their potential role in von Willebrand disease

References 

  1. Von Willebrand EA. Hereditar pseudohemofili. Fin Lakaresallsk Handl. 1926;67:7–112
  2. Sadler JE, Gralnick HR. Commentary: a new classification for von Willebrand disease. Blood. 1994;84:676–679
  3. Miller CH, Graham JB, Goldin LR, Elston RC. Genetics of classic von Willebrand’s disease. I. Phenotypic variation within families. Blood. 1979;54:117–136
  4. Miller CH, Graham JB, Goldin LR, Elston RC. Genetics of classic von Willebrand’s disease. II. Optimal assignment of the heterozygous genotype (diagnosis) by discriminant analysis. Blood. 1979;54:137–145
  5. Mohlke KL, Nichols WC, Ginsburg D. The molecular basis of von Willebrand disease. Int J Clin Lab Res. 1999;29:1–7
  6. Fressinaud E, Mazurier C, Meyer D. Molecular genetics of type 2 von Willebrand disease. Int J Hematol. 2002;75:9–18
  7. Baronciani L, Cozzi G, Canciani MT, et al. Molecular characterization of a multiethnic group of 21 patients with type 3 von Willebrand disease. Thromb Haemost. 2000;84:536–540
  8. Casana P, Martinez F, Haya S, Espinos C, Aznar JA. Significant linkage and non-linkage of type 1 von Willebrand disease to the von Willebrand factor gene. Br J Haematol. 2001;115:692–700
  9. Castaman G, Eikenboom JC, Bertina RM, Rodeghiero F. Inconsistency of association between type 1 von Willebrand disease phenotype and genotype in families identified in an epidemiological investigation. Thromb Haemost. 1999;82:1065–1070
  10. Ginsburg D, Bowie EJ. Molecular genetics of von Willebrand disease. Blood. 1992;79:2507–2519
  11. Vlot AJ, Koppelman SJ, Bouma BN, Sixma JJ. Factor VIII and von Willebrand factor. Thromb Haemost. 1998;79:456–465
  12. Matsui T, Titani K, Mizuochi T. Structures of the asparagine-linked oligosaccharide chains of human von Willebrand factor. Occurrence of blood group A, B, and H(O) structures. J Biol Chem. 1992;267:8723–8731
  13. Varki A. Biological roles of oligosaccharides: all of the theories are correct. Glycobiology. 1993;3:97–130
  14. Sodetz JM, Paulson JC, McKee PA. Carbohydrate composition and identification of blood group A, B, and H oligosaccharide structures on human Factor VIII/von Willebrand factor. J Biol Chem. 1979;254:10754–10760
  15. Mohlke KL, Purkayastha AA, Westrick RJ, et al. Mvwf, a dominant modifier of murine von Willebrand factor, results from altered lineage-specific expression of a glycosyltransferase. Cell. 1999;96:111–120
  16. Jaffe EA, Hoyer LW, Nachman RL. Synthesis of antihemophilic factor antigen by cultured human endothelial cells. J Clin Invest. 1973;52:2757–2764
  17. Nachman R, Levine R, Jaffe EA. Synthesis of factor VIII antigen by cultured guinea pig megakaryocytes. J Clin Invest. 1977;60:914–921
  18. Wagner DD, Marder VJ. Biosynthesis of von Willebrand protein by human endothelial cells: processing steps and their intracellular localization. J Cell Biol. 1984;99:2123–2130
  19. Titani K, Kumar S, Takio K, et al. Amino acid sequence of human von Willebrand factor. Biochemistry (Mosc). 1986;25:3171–3184
  20. Wagner DD, Saffaripour S, Bonfanti R, et al. Induction of specific storage organelles by von Willebrand factor propolypeptide. Cell. 1991;64:403–413
  21. Ruggeri ZM, Ware J. von Willebrand factor. FASEB J. 1993;7:308–316
  22. Samor B, Mazurier C, Goudemand M, Debeire P, Fournet B, Montreuil J. Preliminary results on the carbohydrate moiety of factor VIII/von Willebrand factor (FVIII/vWf). Thromb Res. 1982;25:81–89
  23. Debeire P, Montreuil J, Samor B, et al. Structure determination of the major asparagine-linked sugar chain of human factor VIII–von Willebrand factor. FEBS Lett. 1983;151:22–26
  24. Spik G, Strecker G, Fournet B, et al. Primary structure of the glycans from human lactotransferrin. Eur J Biochem. 1982;121:413–419
  25. Pierce-Cretel A, Pamblanco M, Strecker G, et al. Primary structure of the N-glycosidically linked sialoglycans of secretory immunoglobulins A from human milk. Eur J Biochem. 1982;125:383–388
  26. Samor B, Michalski JC, Debray H, et al. Primary structure of a new tetraantennary glycan of the N-acetyllactosaminic type isolated from human factor VIII/von Willebrand factor. Eur J Biochem. 1986;158:295–298
  27. Matsui T, Shimoyama T, Matsumoto M, et al. ABO blood group antigens on human plasma von Willebrand factor after ABO-mismatched bone marrow transplantation. Blood. 1999;94:2895–2900
  28. Samor B, Michalski JC, Mazurier C, et al. Primary structure of the major O-glycosidically linked carbohydrate unit of human von Willebrand factor. Glycoconj J. 1989;6:263–270
  29. Matsui T, Kihara C, Fujimura Y, Mizuochi T, Titani K. Carbohydrate analysis of human von Willebrand factor with horseradish peroxidase-conjugated lectins. Biochem Biophys Res Commun. 1991;178:1253–1259
  30. Osawa T, Tsuji T. Fractionation and structural assessment of oligosaccharides and glycopeptides by use of immobilized lectins. Annu Rev Biochem. 1987;56:21–42
  31. Gralnick HR, Coller BS, Sultan Y. Carbohydrate deficiency of the factor VIII/von Willebrand factor Protein in von Willebrand’s disease variants. Science. 1976;192:56–59
  32. Ellies LG, Ditto D, Levy GG, et al. Sialyltransferase ST3Gal-IV operates as a dominant modifier of hemostasis by concealing asialoglycoprotein receptor ligands. Proc Natl Acad Sci U S A. 2002;99:10042–10047
  33. Gralnick HR, Sultan Y, Coller BS. Von Willebrand’s disease: combined qualitative and quantitative abnormalities. N Engl J Med. 1977;296:1024–1030
  34. Zimmerman TS, Voss R, Edgington TS. Carbohydrate of the factor VIII/von Willebrand factor in von Willebrand’s disease. J Clin Invest. 1979;64:1298–1302
  35. De Marco L, Shapiro SS. Properties of human asialo-factor VIII. A ristocetin-independent platelet-aggregating agent. J Clin Invest. 1981;68:321–328
  36. Vermylen J, De Gaetano G, Donati MB, Verstraete M. Platelet-aggregating activity in neuraminidase-treated human cryoprecipitates: its correlation with factor-VIII-related antigen. Br J Haematol. 1974;26:645–650
  37. Vermylen J, Donati MB, De Gaetano G, Verstraete M. Aggregation of human platelets by bovine or human factor VIII: role of carbohydrate side chains. Nature. 1973;244:167–168
  38. Rosenfeld L, Kirby EP. The effects of neuraminidase treatment on the biological activities of factor VIII. Thromb Res. 1979;15:255–261
  39. Levy-Toledano S, Caen JP, Halmos T, Mester L. Dissociation between human platelet agglomerating activity and factor VIII procoagulant activity of bovine plasma preparations by chemical treatment. I. Effect of neuraminidase. Pathol Biol (Paris). 1973;21(Suppl):60–62
  40. Sodetz JM, Pizzo SV, McKee PA. Relationship of sialic acid to function and in vivo survival of human factor VIII/von Willebrand factor protein. J Biol Chem. 1977;252:5538–5546
  41. Sodetz JM, Paulson JC, Pizzo SV, McKee PA. Carbohydrate on human factor VIII/von Willebrand factor. Impairment of function by removal of specific galactose residues. J Biol Chem. 1978;253:7202–7206
  42. Kao KJ, Pizzo SV, McKee PA. Factor VIII/von Willebrand protein. Modification of its carbohydrate causes reduced binding to platelets. J Biol Chem. 1980;255:10134–10139
  43. Fukui H, Mikami S, Okuda T, Murashima N, Takase T. Studies of von Willebrand factor: effects of different kinds of carbohydrate oxidases, SH-inhibitors and some other chemical reagents. Br J Haematol. 1977;36:259–270
  44. Morisato DK, Gralnick HR. Selective binding of the factor VIII/von Willebrand factor protein to human platelets. Blood. 1980;55:9–15
  45. Gralnick HR. Factor VIII/von Willebrand factor protein. Galactose a cryptic determinant of von Willebrand factor activity. J Clin Invest. 1978;62:496–499
  46. Goudemand J, Mazurier C, Samor B, Bouquelet S, Montreuil J, Goudemand M. Effect of carbohydrate modifications of factor VIII/von Willebrand factor on binding to platelets. Thromb Haemost. 1985;53:390–395
  47. Gralnick HR, Williams SB, Rick ME. Role of carbohydrate in multimeric structure of factor VIII/von Willebrand factor protein. Proc Natl Acad Sci U S A. 1983;80:2771–2774
  48. Kessler CM, Floyd CM, Frantz SC, Orthner C. Critical role of the carbohydrate moiety in human von Willebrand factor protein for interactions with type I collagen. Thromb Res. 1990;57:59–76
  49. Wagner DD, Mayadas T, Marder VJ. Initial glycosylation and acidic pH in the Golgi apparatus are required for multimerization of von Willebrand factor. J Cell Biol. 1986;102:1320–1324
  50. Federici AB, Elder JH, De Marco L, Ruggeri ZM, Zimmerman TS. Carbohydrate moiety of von Willebrand factor is not necessary for maintaining multimeric structure and ristocetin cofactor activity but protects from proteolytic degradation. J Clin Invest. 1984;74:2049–2055
  51. Berkowitz SD, Federici AB. Sialic acid prevents loss of large von Willebrand factor multimers by protecting against amino-terminal proteolytic cleavage. Blood. 1988;72:1790–1796
  52. Bernard BA, Yamada KM, Olden K. Carbohydrates selectively protect a specific domain of fibronectin against proteases. J Biol Chem. 1982;257:8549–8554
  53. Ashwell G, Harford J. Carbohydrate-specific receptors of the liver. Annu Rev Biochem. 1982;51:531–554
  54. Morell AG, Gregoriadis G, Scheinberg IH, Hickman J, Ashwell G. The role of sialic acid in determining the survival of glycoproteins in the circulation. J Biol Chem. 1971;246:1461–1467
  55. Nelsestuen GL, Suttie JW. Properties of asialo and aglycoprothrombin. Biochem Biophys Res Commun. 1971;45:198–203
  56. Durocher JR, Payne RC, Conrad ME. Role of sialic acid in erythrocyte survival. Blood. 1975;45:11–20
  57. Ain KB, Mori Y, Refetoff S. Reduced clearance rate of thyroxine-binding globulin (TBG) with increased sialylation: a mechanism for estrogen-induced elevation of serum TBG concentration. J Clin Endocrinol Metab. 1987;65:689–696
  58. Stockert RJ, Morell AG, Scheinberg IH. The existence of a second route for the transfer of certain glycoproteins from the circulation into the liver. Biochem Biophys Res Commun. 1976;68:988–993
  59. Baynes JW, Wold F. Effect of glycosylation on the in vivo circulating half-life of ribonuclease. J Biol Chem. 1976;251:6016–6024
  60. Kolatkar AR, Leung AK, Isecke R, Brossmer R, Drickamer K, Weis WI. Mechanism of N-acetylgalactosamine binding to a C-type animal lectin carbohydrate-recognition domain. J Biol Chem. 1998;273:19502–19508
  61. Stoddart JH, Andersen J, Lynch DC. Clearance of normal and type 2A von Willebrand factor in the rat. Blood. 1996;88:1692–1699
  62. Sweeney JD, Novak EK, Reddington M, Takeuchi KH, Swank RT. The RIIIS/J inbred mouse strain as a model for von Willebrand disease. Blood. 1990;76:2258–2265
  63. Mohlke KL, Purkayastha AA, Westrick RJ, Ginsburg D. Comparative mapping of distal murine chromosome 11 and human 17q21.3 in a region containing a modifying locus for murine plasma von Willebrand factor level. Genomics. 1998;54:19–30
  64. Nichols WC, Cooney KA, Mohlke KL, et al. von Willebrand disease in the RIIIS/J mouse is caused by a defect outside of the von Willebrand factor gene. Blood. 1995;86:2461
  65. Orstavik KH, Magnus P, Reisner H, Berg K, Graham JB, Nance W. Factor VIII and factor IX in a twin population. Evidence for a major effect of ABO locus on factor VIII level. Am J Hum Genet. 1985;37:89–101
  66. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood. 1987;69:1691–1695
  67. Souto JC, Almasy L, Muniz-Diaz E, et al. Functional effects of the ABO locus polymorphism on plasma levels of von Willebrand factor, factor VIII, and activated partial thromboplastin time. Arterioscler Thromb Vasc Biol. 2000;20:2024–2028
  68. Lowe JB. The blood group-specific human glycosyltransferases. Baillieres Clin Haematol. 1993;6:465–492
  69. O’Donnell J, Boulton FE, Manning RA, Laffan MA. Amount of H antigen expressed on circulating von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levels. Arterioscler Thromb Vasc Biol. 2002;22:335–341
  70. Brown SA, Collins PW, Bowen DJ. Heterogeneous detection of A-antigen on von Willebrand factor derived from platelets, endothelial cells and plasma. Thromb Haemost. 2002;87:990–996
  71. Sweeney JD, Hoernig LA. Intraplatelet von Willebrand factor and ABO blood group. Thromb Res. 1992;68:393–398
  72. O’Donnell J, Mille-Baker B, Laffan M. Human umbilical vein endothelial cells differ from other endothelial cells in failing to express ABO blood group antigens. J Vasc Res. 2000;37:540–547
  73. O’Donnell J, Laffan MA. The relationship between ABO histo-blood group, factor VIII and von Willebrand factor. Transfus Med. 2001;11:343–351
  74. Eikenboom JC, Castaman G, Kamphuisen PW, Rosendaal FR, Bertina RM. The factor VIII/von Willebrand factor ratio discriminates between reduced synthesis and increased clearance of von Willebrand factor. Thromb Haemost. 2002;87:252–257
  75. de Romeuf C, Mazurier C. Comparison between von Willebrand factor (VWF) and VWF antigen II in normal individuals and patients with von Willebrand disease. Thromb Haemost. 1998;80:37–41
  76. Mannucci PM, Capoferri C, Canciani MT. Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease. Br J Haematol. 2004;126:213–218
  77. Bowen DJ. An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13. Journal of Thrombosis and Haemostasis. 2003;1:33–40
  78. Vlot AJ, Mauser-Bunschoten EP, Zarkova AG, et al. The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A. Thromb Haemost. 2000;83:65–69
  79. Millar CM, Bell RJ, Harrington CM, Pascoe GM, Lee CA, Brown SA. Study of VWF antigen clearance in patients with type 1 von Willebrand disease and reporting of a familial tendency (abstract). Br J Haematol. 2003;121:21
  80. Mannucci P, Canciani T, Rota L, Donovan B. Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand’s disease. Br J Haematol. 1982;47:283–293
  81. Brown SA, Eldridge A, Collins PW, Bowen DJ. Increased clearance of von Willebrand factor antigen post-DDAVP in Type 1 von Willebrand disease: is it a potential pathogenic process. J Thromb Haemost. 2003;1:1714–1717
  82. Michiels JJ, van deVelde A, van Vliet HH, van der Planken M, Schroyens W, Berneman Z. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications. Semin Thromb Hemost. 2002;28:111–132

PII: S0268-960X(05)00020-2

doi: 10.1016/j.blre.2005.02.002

Blood Reviews
Volume 20, Issue 2 , Pages 83-92 , March 2006

Article Tools

* Image Usage & Resolution